Journal of Fungi (Dec 2020)

MixInYeast: A Multicenter Study on Mixed Yeast Infections

  • Narda Medina,
  • Juan Carlos Soto-Debrán,
  • Danila Seidel,
  • Isin Akyar,
  • Hamid Badali,
  • Aleksandra Barac,
  • Stéphane Bretagne,
  • Yasemin Cag,
  • Carole Cassagne,
  • Carmen Castro,
  • Arunaloke Chakrabarti,
  • Eric Dannaoui,
  • Celia Cardozo,
  • Julio Garcia-Rodriguez,
  • Juliette Guitard,
  • Petr Hamal,
  • Martin Hoenigl,
  • Tomasz Jagielski,
  • Sadegh Khodavaisy,
  • Giuliana Lo Cascio,
  • María Carmen Martínez-Rubio,
  • Joseph Meletiadis,
  • Patricia Muñoz,
  • Elżbieta Ochman,
  • Teresa Peláez,
  • Ana Perez-Ayala Balzola,
  • Juergen Prattes,
  • Emmanuel Roilides,
  • Maite Ruíz-Pérez de Pipaón,
  • Raphael Stauf,
  • Jörg Steinmann,
  • Ana Isabel Suárez-Barrenechea,
  • Rocío Tejero,
  • Laura Trovato,
  • Lourdes Viñuela,
  • Thanwa Wongsuk,
  • Iwona Żak,
  • Hossein Zarrinfar,
  • Cornelia Lass-Flörl,
  • Sevtap Arikan-Akdagli,
  • Ana Alastruey-Izquierdo,
  • on behalf of MixInYeast Study Group from EFISG

DOI
https://doi.org/10.3390/jof7010013
Journal volume & issue
Vol. 7, no. 1
p. 13

Abstract

Read online

Invasive candidiasis remains one of the most prevalent systemic mycoses, and several studies have documented the presence of mixed yeast (MY) infections. Here, we describe the epidemiology, clinical, and microbiological characteristics of MY infections causing invasive candidiasis in a multicenter prospective study. Thirty-four centers from 14 countries participated. Samples were collected in each center between April to September 2018, and they were sent to a reference center to confirm identification by sequencing methods and to perform antifungal susceptibility testing, according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST). A total of 6895 yeast cultures were identified and MY occurred in 150 cases (2.2%). Europe accounted for the highest number of centers, with an overall MY rate of 4.2% (118 out of 2840 yeast cultures). Of 122 MY cases, the most frequent combinations were Candida albicans/C. glabrata (42, 34.4%), C. albicans/C. parapsilosis (17, 14%), and C. glabrata/C. tropicalis (8, 6.5%). All Candida isolates were susceptible to amphotericin B, 6.4% were fluconazole-resistant, and two isolates (1.6%) were echinocandin-resistant. Accurate identification of the species involved in MY infections is essential to guide treatment decisions.

Keywords